Video

HER2CLIMB-02: Tucatinib and T-DM1 in HER2+ Breast Cancer

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

Transcript:

Megan Kruse, MD: The HER2CLIMB-02 study is a study in progress that will look at the combination of trastuzumab emtansine with either placebo or tucatinib for patients with metastatic HER2 [human epidermal growth factor receptor 2]–positive breast cancer who have previously received treatment with a taxane and trastuzumab. The idea behind this study is to see if we can improve on our treatment in the second-line setting to determine if there’s any synergy between the combination of T-DM1 [trastuzumab emtansine] with tucatinib.

The clinical situation behind this is CNS [central nervous system] control. We know from other studies with T-DM1 [trastuzumab emtansine] that when patients have disease progression or failure of treatment, 1 of the sites where this can happen is in the brain or CNS. When you add T-DM1 [trastuzumab emtansine] to tucatinib, the hope is that you’re getting better extracranial coverage but also intracranial coverage for micrometastatic disease that’s not known, compared with what you’d be getting with T-DM1 [trastuzumab emtansine] alone or in the trial T-DM1 [trastuzumab emtansine] plus placebo. If this trial is positive, it’s going to make our treatment selection and sequencing very challenging. In a good way, it would open another treatment option for patients. T-DM1 [trastuzumab emtansine] has taken a back seat to T-DXd [trastuzumab deruxtecan] in the second-line setting, based on the results of the DESTINY-Breast03 study.

We also have the tucatinib-based regimen: tucatinib with capecitabine and trastuzumab. That’s another option in the second- and third-line settings. If this HER2CLIMB-02 study is positive, then you’re bringing T-DM1 [trastuzumab emtansine] back and also having a combination regimen that includes tucatinib. It would make that space that’s already fuzzy a little fuzzier in terms of how we should sequence these agents. It leads to the biggest question in our field overall, and 1 of the hardest to answer, because sequencing trials are particularly difficult to accomplish.

Transcript edited for clarity.

Related Videos
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
In this episode of OncChats: Empowering Community Cancer Care, Dr. Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources, and underscores the importance of mentorship programs for community providers to ensure equitable cancer care.
In this episode of OncChats: Empowering Community Cancer Care, Drs Woodworth and Rai, discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.
In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.
Sunil Adige, MD
Margaret E. Gatti-Mays, MD, MPH, FACP
Sunil Adige, MD
Seth Wander, MD, PhD